The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Cellular origin of glioblastoma and its implication in precision therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are multiple lines of evidence that it originates from neural stem cells (NSCs), NSC-derived glial progenitors, and oligodendrocyte precursor cells.41,42,43,44”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Edmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2014.573 · Cited by 2,515
Flagged first, then by citations
Research works printed but not linked: 14
- Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311–1333. · DOI
- He H, Yao M, Zhang W, Tao B, Liu F, Li S et al. MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment. Cell Mol Immunol 2016; 13: 658–668. · DOI
- Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005; 2: 119–130. · DOI
- Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011; 19: 305–316. · DOI
- Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011; 146: 209–221. · DOI
- Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E et al. Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell 2015; 28: 429–440. · DOI
- Ghazi SO, Stark M, Zhao Z, Mobley BC, Munden A, Hover Let al.Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma. J Neuropathol Exp Neurol 2012; 71: 729–740. · DOI
- Zong H. Generation and applications of MADM-based mouse genetic mosaic system. Methods Mol Biol 2014; 1194: 187–201. · DOI
- Zong H, Espinosa JS, Su HH, Muzumdar MD, Luo L. Mosaic analysis with double markers in mice. Cell 2005; 121: 479–492. · DOI
- Lan X, Jörg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 2017; 549: 227–232. · DOI
- Ledur PF, Liu C, He H, Harris AR, Minussi DC, Zhou HY et al. Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells. Neuro-Oncology 2016; 18: 1413–1424. · DOI
- Sreedharan S, Maturi NP, Xie Y, Sundström A, Jarvius M, Libard S et al. Mouse models of pediatric supratentorial high-grade glioma reveal how cell-of-origin influences tumor development and phenotype. Cancer Res 2017; 77: 802–812. · DOI
- Jiang Y, Marinescu VD, Xie Y, Jarvius M, Maturi NP, Haglund C et al. Glioblastoma cell malignancy and drug sensitivity are affected by the cell of origin. Cell Rep 2017; 19: 1080–1081. · DOI
- Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ et al. Long-term Survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res 2017; 23: 1898–1909. · DOI
Cited by
Sorted by citations
MiR-128-3p – a gray eminence of the human central nervous system
Kiel, K., Król, S. K., Bronisz, A., & Godlewski, J. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102141 · Cited by 15
Metadata
- Authors
- Yao, M., Li, S., Wu, X., Diao, S., Zhang, G., He, H., Bian, L., & Lu, Y.
- Venue
- Cellular & Molecular Immunology
- Published
- 2018-03-19
- Volume
- 15
- Issue
- 8
- Pages
- 737-739
- ISSN
- 1672-7681
- 2042-0226
- Cited by
- 94
- References
- 2
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
